

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 December 2003 (24.12.2003)

PCT

(10) International Publication Number  
WO 03/106384 A2

- (51) International Patent Classification?: C07C
- (21) International Application Number: PCT/US03/18962
- (22) International Filing Date: 12 June 2003 (12.06.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/388,255 13 June 2002 (13.06.2002) US  
60/444,429 3 February 2003 (03.02.2003) US
- (71) Applicant (*for all designated States except US*): JOHNS HOPKINS UNIVERSITY [US/US]; Office of Licensing and Technology Development, 3400 N. Charles Street, Baltimore, MD 21218 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): KHAN, Saeed, R., Ph., D. [US/US]; 9702 Watts Road, Owings Mills, MD 21117 (US).
- (74) Agents: BURTON, Carol, W. et al.; Hogan & Hartson, LLP, Suite 1500, 1200 17th Street, Denver, CO 80202 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A2  
WO 03/106384

(54) Title: NOVEL BORONIC CHALCONE DERIVATIVES AND USES THEREOF

(57) **Abstract:** The present invention relates to novel boronic chalcone derivatives which are useful as antitumor/anticancer agents. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good inhibitors of the growth of human breast cancer cells. The present invention also relates to the use of the novel boronic chalcone derivatives to treat cancer. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of cancer.

The present application claims priority of U.S. Provisional Patent Application No. 60/388,255 filed June 13, 2002, and U.S. Provisional Patent Application No. 60/444,429 filed February 3, 2003, both of which are incorporated herein in their entirety by this reference.

NOVEL BORONIC CHALCOINE DERIVATIVES AND USES THEREOF

RELATED APPLICATIONS

This invention relates to novel boronic chalcocine compounds and uses thereof. The compounds of this invention are particularly useful for the treatment of tumors and cancers.

Field of the Invention

Background of the State of the Art

Throughout this application, various publications are referenced by author and date. Full citations for these publications may be found listed at the end of the specification immediately preceding the claims. The disclosures of these publications are hereby incorporated by reference in their entirety and referred to herein as of the date of this invention described at as known to those skilled herein as of the date of this invention described and claimed herein.

Breast cancer is expected to account for 203,500 new cancer cases and 39,600 deaths in 2002 (Jemal, A. et al., CA Cancer J. Clin., 2002, 52, 23-47). Although major advances have been made in early detection, prevention, and treatment, the need for more effective therapy in the fight against late stage breast cancer continues. Currently there is no curative treatment for women with metastatic breast cancer once they have failed adjuvant therapies. New and effective cytotoxic agents with novel mechanisms of action are therefore urgently needed for the treatment of women with metastatic breast cancer. Hormone and chemotherapy, while of substantial palliative benefit, has had little impact on overall survival and the

25

and 39,600 deaths in 2002 (Jemal, A. et al., CA Cancer J. Clin., 2002, 52, 23-47). Although major advances have been made in early detection, prevention, and treatment, the need for more effective therapy in the fight against late stage breast cancer continues. Currently there is no curative treatment for women with metastatic breast cancer once they have failed adjuvant therapies. New and effective cytotoxic agents with novel mechanisms of action are therefore urgently needed for the treatment of women with metastatic breast cancer. Hormone and chemotherapy, while of substantial palliative benefit, has had little impact on overall survival and the

20

art as known to those skilled herein as of the date of this invention described and claimed herein.

Breast cancer is expected to account for 203,500 new cancer cases and 39,600 deaths in 2002 (Jemal, A. et al., CA Cancer J. Clin., 2002, 52, 23-47). Although major advances have been made in early detection, prevention, and treatment, the need for more effective therapy in the fight against late stage breast cancer continues. Currently there is no curative treatment for women with metastatic breast cancer once they have failed adjuvant therapies. New and effective cytotoxic agents with novel mechanisms of action are therefore urgently needed for the treatment of women with metastatic breast cancer. Hormone and chemotherapy, while of substantial palliative benefit, has had little impact on overall survival and the

20

art as known to those skilled herein as of the date of this invention described and claimed herein.

Breast cancer is expected to account for 203,500 new cancer cases and 39,600 deaths in 2002 (Jemal, A. et al., CA Cancer J. Clin., 2002, 52, 23-47). Although major advances have been made in early detection, prevention, and treatment, the need for more effective therapy in the fight against late stage breast cancer continues. Currently there is no curative treatment for women with metastatic breast cancer once they have failed adjuvant therapies. New and effective cytotoxic agents with novel mechanisms of action are therefore urgently needed for the treatment of women with metastatic breast cancer. Hormone and chemotherapy, while of substantial palliative benefit, has had little impact on overall survival and the

15

art as known to those skilled herein as of the date of this invention described and claimed herein.

Breast cancer is expected to account for 203,500 new cancer cases and 39,600 deaths in 2002 (Jemal, A. et al., CA Cancer J. Clin., 2002, 52, 23-47). Although major advances have been made in early detection, prevention, and treatment, the need for more effective therapy in the fight against late stage breast cancer continues. Currently there is no curative treatment for women with metastatic breast cancer once they have failed adjuvant therapies. New and effective cytotoxic agents with novel mechanisms of action are therefore urgently needed for the treatment of women with metastatic breast cancer. Hormone and chemotherapy, while of substantial palliative benefit, has had little impact on overall survival and the

10

art as known to those skilled herein as of the date of this invention described and claimed herein.

Breast cancer is expected to account for 203,500 new cancer cases and 39,600 deaths in 2002 (Jemal, A. et al., CA Cancer J. Clin., 2002, 52, 23-47). Although major advances have been made in early detection, prevention, and treatment, the need for more effective therapy in the fight against late stage breast cancer continues. Currently there is no curative treatment for women with metastatic breast cancer once they have failed adjuvant therapies. New and effective cytotoxic agents with novel mechanisms of action are therefore urgently needed for the treatment of women with metastatic breast cancer. Hormone and chemotherapy, while of substantial palliative benefit, has had little impact on overall survival and the

10

art as known to those skilled herein as of the date of this invention described and claimed herein.

Breast cancer is expected to account for 203,500 new cancer cases and 39,600 deaths in 2002 (Jemal, A. et al., CA Cancer J. Clin., 2002, 52, 23-47). Although major advances have been made in early detection, prevention, and treatment, the need for more effective therapy in the fight against late stage breast cancer continues. Currently there is no curative treatment for women with metastatic breast cancer once they have failed adjuvant therapies. New and effective cytotoxic agents with novel mechanisms of action are therefore urgently needed for the treatment of women with metastatic breast cancer. Hormone and chemotherapy, while of substantial palliative benefit, has had little impact on overall survival and the

5

art as known to those skilled herein as of the date of this invention described and claimed herein.

Breast cancer is expected to account for 203,500 new cancer cases and 39,600 deaths in 2002 (Jemal, A. et al., CA Cancer J. Clin., 2002, 52, 23-47). Although major advances have been made in early detection, prevention, and treatment, the need for more effective therapy in the fight against late stage breast cancer continues. Currently there is no curative treatment for women with metastatic breast cancer once they have failed adjuvant therapies. New and effective cytotoxic agents with novel mechanisms of action are therefore urgently needed for the treatment of women with metastatic breast cancer. Hormone and chemotherapy, while of substantial palliative benefit, has had little impact on overall survival and the

mortality rate from metastatic breast cancer. At the present time standard treatments for metastatic breast cancer include paclitaxel in combination with vinca alkaloids, etoposide, and other regimens that include agents such as anthacyclines, alkylating agents, antimetabolites, tamoxifen, and aromatase 5 inhibitors (Chabner BA, Collins JM, *Cancer chemotherapy principal and practice*, pp 9-13, and 40-85. B. Lippincott Company, Philadelphia, 1990). The ultimate conclusion of these numerous studies over the last 50 years is that although these therapies provides significant palliative effect in the majority of with metastatic breast patients, it is likely to be curative. Although 10 major advances have been made in early detection, prevention, and treatment of early disease, the need for more effective therapy in the fight against late stage breast cancer continues.

Recently the mouse double minute 2 (MDM2) oncogene has been suggested as a target for breast cancer therapy (Juven-Gershon, T. and 15 Oren, M. *Mol. Med.*, 1999, 5, 71-83; Mornand, J. et al., *Nucleic Acids Res.*, 1998, 26, 3453-3459). MDM2 is amplified or overexpressed in human breast cancer, and MDM2 levels are associated with poor prognosis of human breast cancer. The oncoprotein MDM2 inhibits the tumor suppressor protein p53 by binding to the p53 transactivation domain. The p53 gene is inactivated in 20 human cancer either by mutations or by binding to oncogenic proteins such as MDM2 (Lane, D. P. and Hall, P. A., *Trends Biochem. Sci.*, 1997, 22, 372-374; Oliner, J. D. et al., *Nature*, 1992, 358, 80-83; Lozano, G.; Montes de Oca Luna, R., *Biochim. Biophys. Acta*, 1998, 1377, M55-M59; Wang, H. et al., *Clinical Cancer Res.*, 2001, 7, 3613-3624). In breast tumors, over expression 25 of MDM2 inactivates an otherwise intact p53, disabling the genome integrity checkpoint and allowing cell cycle progression of defective cells (Boyd, M. T. et al., *J. Biol. Chem.*, 2000, 275, 31883-31890). Studies comparing MDM2 overexpression and p53 mutation concluded that these are mutually exclusive events, supporting the notion that the primary impact of MDM2 amplification in 30 cancer cells is the inactivation of the endogenous wild-type p53 (Wang et al., *supra*). It has been shown recently that a peptide homologue of p53 is

- 5 sufficient to induce p53-dependent death of cells overexpressing MDM2 (Wasyluk, C., et al., *Oncogene*, 1999, 18, 1921-1934). This result provides clear evidence that disruption of the p53/MDM2 complex might be effective in cancer therapy. It has been shown that MDM2 addititionally has a role in tumor growth p53-independent mechanisms (Baker, S., et al., *Science*, 1990, 249, 912-915; Diller, L., et al., *Mol. Cell. Biol.*, 1990, 10, 5772-5781; Fakhrazadeh, S., et al., *EMBO J.*, 1991, 10, 1565; Lundgren, K.; Motes de Oca Luna, R., et al., *Genes Dev.*, 1997, 11, 714-725; Zhang, R., and Wang, H., *Curr. Pharm. Des.*, 2000, 6, 393-416; Chabner, B.A., and Collins, J.M., *Cancer Chemotherapy principle and practice*; Lippincott Williams & Wilkins Publishers; Philadelphia, 1990; pp 9-13 and 40-45B).
- 10 Chalocenes are a class of anticancer agents that have shown promising therapeutic efficacy for the management of human cancers. Chalocenes, considered as the precursor of flavonoids and isoflavonoids, are abundant in edible plants. Chemically they comprise open-chain flavonoids in which the two aromatic rings are joined by a three-carbon α,β-unsaturated carbonyl system. For example, chalocenes have been observed to inhibit the proliferation of both established and primary ovarian cancer cells (De Vincenzo, R., et al., *Anticancer Drug Des.*, 1995, 10, 481-490). In vivo, chalocenes have been demonstrated to be effective as antitumor agents in skin carcinogenesis (Statomi, Y., *Int. J. Cancer*, 1993, 55, 506-514; Yamamoto, S., et al., *Carcinogenesis*, 1991, 12, 317-323) and chemopreventive agents in several experimental models (Makita, H., et al., *Cancer Res.*, 1996, 56, 4904-4909; Rui, H., *J. Cell. Biochem.*, 1997, 67, 7-11; Wattnerberg, L.W., et al., *Cancer Lett.*, 1994, 83, 165-169). Recent studies have shown that these chalocenes induce apoptosis in variety of cell types including breast cancers (Claude-Alain, 15 Mol. Biol., 2002, 28, 315-322; Solli, R., et al., *Biochemistry*, 2001, 40, 336-344; C., et al., *Anticancer Res.*, 2001, 21, 3949-3956; WO 01/17988; WO 96/19209; U.S. Patent No. 5,808,137; Maggiolini, M., et al., *J. Stereol Biotech.* 20, DICesere, N. and Laskowicz, J.R., *Tetrahedron Lett.*, 2002, 43, 2615-2618).
- 20 Biochemical experiments have shown that these compounds could disrupt the induce apoptosis in variety of cell types including breast cancers (Claude-Alain, 25 C., et al., *Anticancer Res.*, 2001, 21, 3949-3956; WO 01/17988; WO 96/19209; U.S. Patent No. 5,808,137; Maggiolini, M., et al., *J. Stereol Biotech.* 20, DICesere, N. and Laskowicz, J.R., *Tetrahedron Lett.*, 2002, 43, 2615-2618).

MDM2/p53 protein complex, releasing p53 from both the p53/MDM2 and DNA-bound p53/MDM2 complexes (Stoll et al., *supra*).

- Carboxylic chalcones have shown promising therapeutic efficacy for the management of human cancers (Daskiewicz, J. B., et al., *Tetrahedron Lett.* 1999, **40**, 7095-7098; Devincenzo, R., et al., *Anti-Cancer Drug Des.* 1995, **10**, 481-490). Previous studies (Stoll et al., *supra*; Kussie, P. H., et al., *Science*, 1996, **274**, 948-953) on the binding modes of carboxylic acid analogs of chalcones with MDM2 revealed that the carboxylic acid group could be placed near the base of lysine51 (K51), which is found in a salt bridge interaction with glutamic acid 25 (E25). It was presumed that the acid group of the chalcone forms a salt bridge with K51 and simultaneously breaks the salt bridge with E25 of the MDM2. However, carboxylic acid analogs of chalcone reported in the literature (Stoll et al., *supra*) are equally toxic to both normal and malignant breast epithelial cells. The toxicity to normal breast cells may be due to MDM2/p53 independent mechanisms. Therefore, a chalcone derivative that could strongly and irreversibly bind to and disrupt MDM2 protein complexes may be selectively toxic to MDM2 overexpressing breast cancer cells.

- Boronic acids are Lewis acids and isosteres of carboxylic acid. The pKa's of boronic acids are about 9-10, and therefore at physiological pH boronic acids remain unionized (Tongcharoensirikul, P., et al., *Abstracts of Papers*, 222<sup>nd</sup> ACS national meeting, Chicago, IL, August 26-30; American chemical society, Washington, DC, 2001; MEDI-224). Thus, a coordinate covalent bond (boron-nitrogen) can be formed between a electron deficient boronic acid moiety and electron donating amino group, which may strongly enhance binding of boronic-chalcones with the lysine 51 of MDM2 at neutral pH when compared to the corresponding carboxylic acid analog of chalcones.

- Boronic chalcone analogs have been previously described. These compounds have been used as fluorescent probes that may be useful for detection of fluorides (DiCesare, N. and Lakowicz, J. R., *supra*) and

## SUMMARY OF THE INVENTION

saccharides such as glucose that may be applicable to the design of biosensors for diabetes (DiCesare, N. and Lakowicz, J. R., *supra*). However, prior to this invention no investigations into the antidiabetic activity of boronic-chalcogenes on different cancer cell lines have been reported.


The present invention further investigates the potential value of utilizing as a drug target for breast cancer therapy. For example, a chalcone derivative of this invention that inhibits MDM2 expression or binds to and disrupts the MDM2 protein complex may be a useful compound for the treatment of breast cancer. While not wishing to be bound by any theory, it is believed that the boronic acid analog might form a stronger salt bridge with K51 of MDM2 than the corresponding carboxylic acid analogs of chalcones and will selectively inhibit growth of breast cancer cells. Accordingly, a set of boronic acid-chalcone derivatives were designed and tested their ability to selectively kill breast cancer over normal breast epithelial cells.

In general, one embodiment of the invention relates to boronic-chemical compounds of the general formula I:

20 disrupts the MDM2 protein complex may be a useful compound for the treatment of breast cancer. While not wishing to be bound by any theory, it is believed that the boronic acid analog might form a stronger salt bridge with K51 of MDM2 than the corresponding carboxylic acid analogs of chalcones and will selectively inhibit growth of breast cancer cells. Accordingly, a set of boronic acid-chalcone derivatives were designed and tested their ability to selectively kill breast cancer over normal breast epithelial cells.

25 In general, one embodiment of the invention relates to boronic-

chalcone compounds of the general formula:




where

- Ar is aryl or heteroaryl, each of which may be substituted or  
5 unsubstituted;
- W is H,  $Z_n$ -F,  $Z_n$ -Cl,  $Z_n$ -Br,  $Z_n$ -I,  $Z_n$ -CF<sub>3</sub>,  $Z_n$ -NO<sub>2</sub>,  $Z_n$ -OR<sup>1</sup>,  $Z_n$ -NR<sup>1</sup>R<sup>2</sup>,  $Z_n$ -COOR<sup>1</sup>,  $Z_n$ -SR<sup>1</sup>,  $Z_n$ -(C=O)R<sup>1</sup>,  $Z_n$ -O(C=O)R<sup>1</sup>,  $Z_n$ -NR<sup>1</sup>(C=O)R<sup>1</sup>,  $Z_n$ -(C=O)NR<sup>1</sup>,  
alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl,  
heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl,  $Z_n$ -Ar  
10 or  $Z_n$ -heteroaryl, wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl,  
heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  
 $Z_n$ -heterocycloalkyl,  $Z_n$ -Ar or  $Z_n$ -heteroaryl may be substituted or  
unsubstituted;
- X is  $Z_n$ ,  $Z_n$ -O,  $Z_n$ -S,  $Z_n$ -NR<sup>1</sup>,  $Z_n$ -NR<sup>1</sup>(C=O),  $Z_n$ -C=O,  $Z_n$ -OC(=O), or  $Z_n$ -  
15 C(=O)O;
- $R^1$  and  $R^2$  are independently H, an amine protecting group, an alcohol  
protecting group, an acid protecting group, a sulfur protecting group, alkyl,  
allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl,  
alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl,  $Z_n$ -Ar or  $Z_n$ -heteroaryl,  
20 wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl,  
heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -  
heterocycloalkyl,  $Z_n$ -Ar or  $Z_n$ -heteroaryl may be substituted or unsubstituted,  
or  $R^1$  together with  $R^2$  and N forms a saturated or partially unsaturated  
heterocycle ring having 1 or more heteroatoms in said ring, wherein said  
25 heterocycle may be substituted or unsubstituted and wherein said heterocycle  
may be fused to an aromatic ring;

L

where Ar is as defined above and R<sub>4</sub> is H, an amine protecting group, Z-OR<sub>1</sub>, Z-SR<sub>1</sub>, Z-NR<sub>1</sub>, Z-(C=O)R<sub>1</sub>, Z-C(=O)R<sub>1</sub>, Z-OC(=O)R<sub>1</sub>, Z-C(=O)OR<sub>1</sub>, alkyl, alkenyl, alkylnyl, heteroalkyl, heteroallyl, heteroallyl, heteroalkenyl,




20

General Formula

In another embodiment, this invention relates to compounds of the

Compounds of Formula II are also described.

where Ar, W, X and n are as defined above and R<sub>1</sub> is an electron-withdrawing moiety. The invention is also directed to pharmaceutically acceptable products, pharmaceutically active metabolites, and pharmaceutically acceptable salts of the compound of Formula I. Methods of making the



5

where  $Ar$ ,  $W$ ,  $X$  and  $n$  are as defined above and  $R$  is an electrical-welding

General Formula II

In another embodiment, this invention relates to compounds of the

are also described.

The invention is also directed to pharmaceutical compounds of Formula I.

$n$  is zero or any integer.

heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl,  $Z_n$ -Ar or  $Z_n$ -heteroaryl, wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl,  $Z_n$ -Ar or  $Z_n$ -heteroaryl may be substituted or

- 5 unsubstituted, and where  $Z_n$ , R<sup>1</sup> and n are as defined above. The invention is also directed to pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts of the compound of Formula III. Methods of making the compounds of Formula III are also described.

- 10 The invention further relates to a method for treating proliferative diseases such as cancers. More specifically, one embodiment of this invention provides a method of treating or preventing a tumor or cancer in a patient comprising administering to said patient in need thereof an effective amount of a compound having the Formula I-III or a pharmaceutically-  
15 acceptable salt or *in vivo* cleavable prodrug thereof. Other aspects of the invention include methods for treating cancers mediated by MDM2. Examples of cancers that may be treated or prevented by the compounds of this invention include, but are not limited to, breast, colorectal, cervical, ovarian, brain, acute leukemia, gastric, non-small cell lung, pancreatic, and renal  
20 cancer.

- The invention also features methods of combination therapy, such as a method for treating cancer, wherein the above methods further include providing radiation therapy or chemotherapy. The chemotherapy or radiation therapy may be administered before, concurrently, or after the administration  
25 of a disclosed compound according to the needs of the patient.

- In a further aspect the present invention provides methods of inhibiting MDM2 expression in a mammal, comprising administering an amount of a compound effective to inhibit said expression, said compound having the Formula I-III or a pharmaceutically acceptable salt or *in vivo* cleavable  
30 prodrug thereof.

The invention features novel boronic chalcone compounds having Formulas I-III, pharmaceutical compositions thereof, and methods of using such compounds and compositions. The inventive compounds of the formulas I-III are useful, for example, for treating a tumor or cancer in a patient. Such compounds have particular utility as therapeutic agents for diseases that can be treated by the inhibition of MDM2 expression.

#### Detailed Description of the Invention

Figure 4 shows a reaction scheme for the synthesis of compound 19.

20 and 15.

Figure 3 shows a reaction scheme for the synthesis of compounds 1-4.

Figure 2 shows a reaction scheme for the synthesis of compounds e.

Figure 1 shows a reaction scheme for the synthesis of compound 1.

• [See full Figure](#)

The accompanying drawings, which are incorporated herein and form a part of the specification, illustrate non-limiting embodiments of the present invention, and together with the description, serve to explain the principles of the invention.

## BRIEF DESCRIPTION OF THE FIGURES

Additional advantages and novel features of this invention shall be set forth in part in the description that follows, and in part will become apparent to those skilled in the art upon examination of the following specification or may be learned by the practice of the invention. The advantages of the invention may be realized and attained by means of the instruments, combinations, compositions, and methods particularly pointed out in the appended claims.


The invention also relates to pharmaceutical compositions comprising an effective amount of an agent selected from compounds of Formulas I-III or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof.

The term "tumor" as used herein refers to abnormal growth in tissue which occurs when cellular proliferation is more rapid than normal tissue and continues to grow after the stimuli that initiated the new growth cease. Tumors generally exhibit partial or complete lack of structural organization and

- 5 functional coordination with the normal tissue, and usually form a distinct mass of tissue which may be benign (benign tumor) or malignant (carcinoma). Tumors tend to be highly vascularized.

- The term "cancer" is used as a general term herein to describe malignant tumors or carcinoma. These malignant tumors may invade  
 10 surrounding tissues, may metastasize to several sites and are likely to recur after attempted removal and to cause death of the patient unless adequately treated. As used herein, the terms carcinoma and cancer are subsumed under the term tumor.

- In general, one embodiment of the invention relates to novel boronic  
 15 chalcone compounds of the general Formula I:



where

- Ar is aryl or heteroaryl, each of which may be substituted or unsubstituted;  
 20 W is H, Z<sub>n</sub>-F, Z<sub>n</sub>-Cl, Z<sub>n</sub>-Br, Z<sub>n</sub>-I, Z<sub>n</sub>-CF<sub>3</sub>, Z<sub>n</sub>-NO<sub>2</sub>, Z<sub>n</sub>-OR<sup>1</sup>, Z<sub>n</sub>-NR<sup>1</sup>R<sup>2</sup>, Z<sub>n</sub>-COOR<sup>1</sup>, Z<sub>n</sub>-SR<sup>1</sup>, Z<sub>n</sub>-(C=O)R<sup>1</sup>, Z<sub>n</sub>-O(C=O)R<sup>1</sup>, Z<sub>n</sub>-NR<sup>1</sup>(C=O)R<sup>1</sup>, Z<sub>n</sub>-(C=O)NR<sup>1</sup>, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z<sub>n</sub>-cycloalkyl, Z<sub>n</sub>-heterocycloalkyl, Z<sub>n</sub>-Ar or Z<sub>n</sub>-heteroaryl, wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z<sub>n</sub>-cycloalkyl,



thienyl, pyrrolyl, pyrazolyl, pyrimidinyl, imidazolyl, indolyl, quinolyl, benzopyranyl, thiazolyl, oxazolyl, isoxazolyl, thiophenyl, 1,3,4-triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyridazinyl, indolyl, and derivatives thereof.

- Alkyl groups include aliphatic (i.e., hydrocarbyl or hydrocarbon radical structures containing hydrogen and carbon atoms) with a free valence. Alkyl groups are understood to include straight chain and branched structures. The alkyl group can be substituted with one or more substituents which are independently selected from the substituents described herein. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, tert-pentyl, hexyl, isoheptyl, and the like.

- Alkenyl groups are analogous to alkyl groups, but have at least one double bond (two adjacent sp<sup>2</sup> carbon atoms). Depending on the placement of a double bond and substituents, if any, the geometry of the double bond 15 may be entgegen (E), or zusammen (Z), cis, or trans. Similarly, alkynyl groups are analogous to alkyl groups, but have at least one triple bond (two adjacent sp carbon atoms). Unsaturated alkenyl or alkynyl groups may have one or more double or triple bonds, respectively, or a mixture thereof; like alkyl groups, unsaturated groups may be straight chain or branched, and they 20 may be substituted as described both above for alkyl groups and throughout the disclosure by example. The alkenyl or alkynyl groups can be substituted with one or more substituents which are independently selected from the substituents described herein.

- The term "alkylene" means a linear or branched saturated divalent 25 hydrocarbon radical of one to twelve carbon atoms, e.g., methylene, ethylene, propylene, 2-methylpropylene, pentylene, and the like.

- The term "alkenylene" refers to a linear or branched divalent hydrocarbon radical of two to twelve carbons containing at least one double bond, wherein the alkenylene radical may be optionally substituted 30 independently with one or more substituents described herein. Examples

unsaturated cyclic radical of 3 to 8 ring atoms in which at least one ring atom

The term "heterocyclically" refers to a saturated or partially

encompasses alkoxyl and heteroalkoxy radicals.

with one or more substituents described herein. The term "heteroalkyl" 25  
radical). The heteroalkyl radical may be optionally substituted independently  
radical (i.e., the heteroatom may appear in the middle or at the end of the  
O, or S, and wherein the radical may be a carbon radical or heteroatom  
least one of the carbon atoms is replaced with a heteroatom selected from N,  
monovalent hydrocarbon radical of one to twelve carbon atoms, wherein at  
The term "heteroalkyl" refers to saturated linear or branched chain  
to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.

saturated or partially unsaturated cycloalkyl or heterocycloalkyl ring of an aryl  
or heteroaryl ring. Examples of cycloalkyl groups include, but are not limited  
and tricyclic cycloalkyl structures, wherein the bicyclic and tricyclic structures  
substituents described herein. The term "cycloalkyl" further includes bicyclic  
cycloalkyl may be optionally substituted independently with one or more  
hydrocarbon radical having from three to twelve carbon atoms, wherein the  
The term "cycloalkyl" refers to saturated or partially unsaturated cyclic  
substituents described herein.

wherein the allyl may be optionally substituted independently with one or more  
heterocycloalkyl, aryl, heteroaryl, or any substituent as defined herein,  
wherein R<sup>1</sup> and R<sup>2</sup> are independently allyl, alkenyl, alkynyl, cycloalkyl,  
The term "allyl" refers to a radical having the formula  $R^1C=CHCR^2$ ,

more substituents described herein.  
the alkynylene radical may be optionally substituted independently with one or  
radical of two to twelve carbons containing at least one triple bond, wherein  
The term "alkynylene" to a linear or branched diivalent hydrocarbon  
include, but are not limited to, ethynylene, propynylene, and the like.

- is a heteroatom selected from nitrogen, oxygen and sulfur, the remaining ring atoms being C where one or more ring atoms may be optionally substituted independently with one or more substituent described below. The radical may be a carbon radical or heteroatom radical. "Heterocycloalkyl" also includes
- 5 radicals where heterocycle radicals are fused with aromatic or heteroaromatic rings. Examples of heterocycloalkyl rings include, but are not limited to, piperidyl, quinolyl, isothiazolyl, piperidinyl, morpholinyl, piperazinyl, tetrahydrofuryl, tetrahydropyrrolyl, pyrrolidinyl, octahydroindolyl, octahydrobenzothifuranyl, and octahydrobenzofuranyl.
- 10 The term "heteroalkenyl" refers to linear or branched-chain monovalent hydrocarbon radical of two to twelve carbon atoms, containing at least one double bond, e.g., ethenyl, propenyl, and the like, wherein at least one of the carbon atoms is replaced with a heteroatom selected from N, O, or S, and wherein the radical may be a carbon radical or heteroatom radical (i.e., the
- 15 heteroatom may appear in the middle or at the end of the radical). The heteroalkenyl radical may be optionally substituted independently with one or more substituents described herein, and includes radicals having "cis" and "trans" orientations, or alternatively, "E" and "Z" orientations.
- The term "heteroalkynyl" refers to a linear or branched monovalent hydrocarbon radical of two to twelve carbon atoms containing at least one triple bond. Examples include, but are not limited to, ethynyl, propynyl, and the like, wherein at least one of the carbon atoms is replaced with a heteroatom selected from N, O, or S, and wherein the radical may be a carbon radical or heteroatom radical (i.e., the heteroatom may appear in the
- 20 middle or at the end of the radical). The heteroalkynyl radical may be optionally substituted independently with one or more substituents described herein.

- The term "heteroallyl" refers to radicals having the formula  $RC=CHCHR^1$ , wherein R and R<sup>1</sup> are independently alkyl, alkenyl, alkynyl,
- 25 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or any substituent as defined

|   |   |
|---|---|
| The term "alcohol protecting group" refers to those organic groups intended to protect alcohol groups or substituents against undesirable reactions during synthetic procedures and include, but are not limited to, benzyl, trimethylsilyl(ethoxy)methyl (SEM), tert-butyl, triflyl and the like.  | The term "sulfur protecting groups" refers to those organic groups intended to protect sulfur groups or substituents against undesirable reactions during synthetic procedures and include, but are not limited to, benzyl, trimethylsilyl(ethoxy)methyl (SEM), tert-butyl, triflyl and the like.             |
| The term "amino protecting group" refers to those organic groups intended to protect nitrogen atoms against undesirable reactions during synthetic procedures and include, but are not limited to, benzyl, trimethylsilyl(ethoxy)methyl (SEM), tert-butyl, methoxyethyl (MOM), and the like.  | The term "carboxyl protecting group" refers to those organic groups intended to protect carboxyl groups or substituents against undesirable reactions during synthetic procedures and include, but are not limited to, benzyl, trimethylsilyl(ethoxy)methyl (SEM), tert-butyl, trifluoroacetyl, and the like. |
| The term "halogen protecting group" refers to those organic groups intended to protect halogen atoms with an electron withdrawing moiety.   | The term "heteroatom protecting group" refers to those organic groups intended to protect heteroatoms such as nitrogen, oxygen, and sulfur.   |
| As used herein, the term "electron withdrawing moiety" is known in the art, and refers to a group which has a greater electron withdrawing effect than halogens (e.g., fluoro, chloro, bromo, and iodo groups), $\text{NO}_2$ , $\text{NH}_2$ , $\text{CN}$ , $\text{SO}_2^+$ , $\text{SO}_2\text{Ar}$ , $\text{COOH}$ , $\text{OAr}$ , $\text{COOR}'$ , $\text{OR}'$ , $\text{COR}'$ , $\text{SH}$ , $\text{SR}'$ , $\text{CF}_3$ , $\text{Ar}$ , alkanyl, alkynyl or allyl, wherein said $\text{Ar}$ , alkynyl, alkynyl and allyl may be optionally substituted or substituted with an electron withdrawing moiety. | The term "heteroatom withdrawing group" refers to those organic groups intended to protect heteroatoms such as nitrogen, oxygen, and sulfur.  |
| herein, wherein at least one of the carbon substituents described herein is selected from N, O, or S, and wherein the radical may be a carbon radical or heteroatom radical (i.e., the heteroatom may appear in the middle or at the end of the radical). The heteroallyl may be optionally substituted independently with an electron withdrawing moiety.  | The term "heteroallyl" may be optionally substituted with an electron withdrawing moiety.   |

(trimethylsilyl)ethoxymethyl (SEM), methylethyl and tert-butyl esters, and the like.

In general, the various moieties or functional groups of the compounds of Formulas I-III may be optionally substituted by one or more substituents.

Examples of substituents suitable for purposes of this invention include, but

- 5 are not limited to, F, Cl, Br, I, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl,  $Z_n$ -OR<sup>1</sup>,  $Z_n$ -NO<sub>2</sub>,  $Z_n$ -CN,  $Z_n$ -CO<sub>2</sub>R<sup>1</sup>,  $Z_n$ -(C=O)R<sup>1</sup>,  $Z_n$ -O(C=O)R<sup>1</sup>,  $Z_n$ -O-alkyl,  $Z_n$ -OAr,  $Z_n$ -SH,  $Z_n$ -SR<sup>1</sup>,  $Z_n$ -SOR<sup>1</sup>,  $Z_n$ -SO<sub>2</sub>R<sup>1</sup>,  $Z_n$ -S-Ar,  $Z_n$ -SOAr,  $Z_n$ -SO<sub>2</sub>Ar,  $Z_n$ -Ar,  $Z_n$ -heteroaryl, Zn-(C=O)NR<sup>1</sup>R<sup>2</sup>,  $Z_n$ -NR<sup>1</sup>R<sup>2</sup>,  $Z_n$ -NR<sup>1</sup>(C=O)R<sup>1</sup>,  $Z_n$ -SO<sub>2</sub>NR<sup>1</sup>R<sup>2</sup>, PO<sub>3</sub>H<sub>2</sub>, SO<sub>3</sub>H<sub>2</sub>, amine protecting groups, alcohol 10 protecting groups, sulfur protecting groups, or acid protecting groups, where:

$Z$  is alkylene having from 1 to 4 carbons, or alkenylene or alkynylene each having from 2 to 4 carbons, wherein said alkylene, alkenylene, or alkynylene may be substituted or unsubstituted;

- 15  $n$  is zero or any integer,

- R<sup>1</sup> and R<sup>2</sup> are alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl, or  $Z_n$ -heterocycloalkyl, Ar or heteroaryl, wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl, Ar, or heteroaryl may be substituted or 20 unsubstituted.

- The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof. Unless indicated otherwise, the 25 description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. Accordingly, this invention also includes racemates and resolved enantiomers, and diastereomers compounds of the Formulas I-III. The methods for the determination of stereochemistry and the separation of

Certain of the compounds of this invention, in pharmaceutical dosage form, may be used as a method of treating a cancer or as a prophylactic agent for preventing a disease or condition from manifesting itself.

Accordingly, this invention further includes compositions including, but not limited to, solvates, pharmaceutically acceptable salts of pharmaceutical active metabolites, and pharmaceutically acceptable salts of compounds of Formulas I-III. The term "solvate" refers to an aggregate of a molecule with one or more solvent molecules.

In certain pharmaceutical dosage forms, the pro-drug form of the compounds according to the present invention may be preferred. A "prodrug is a compound that may be converted under physiological conditions or by solvolysis to the specific compound or to a pharmaceutically acceptable salt of such compound.


In certain pharmaceutical dosage forms, the pro-drug form of the compounds according to the present invention may be preferred. A "product is a compound that may be converted under physiological conditions or by solvolysis to the specified compound or to a pharmaceutically acceptable salt thereof. Metabolites of a compound in the body of a specified compound product produced through metabolism in the body may be identified using techniques known in the art and their activities determined using tests such as that thereof.

A "pharmaceutically active metabolite" is a pharmaceutically active compound of such compounds.

*Pharmaceutical Sciences*, 77:285 (1988); and e) N. Kakeya, et al., *Chem. Pharm. Bull.*, 32: 692 (1984).


The compounds of this invention, including prodrug forms of these agents, can be provided in the form of pharmaceutically acceptable salts. As used herein, the term pharmaceutically acceptable salts or complexes refers to appropriate salts or complexes of the active compounds according to the present invention which retain the desired biological activity of the parent compound and exhibit limited toxicological effects to normal cells. Nonlimiting examples of such salts are acid addition salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, and polyglutamic acid, among others

15 The inventive compounds may be prepared using the reaction routes and synthesis schemes as described below, employing the techniques available in the art using starting materials that are readily available. For example, in one embodiment boronic chalcone compound (4), which is based upon a chemical structure I:



can be prepared according to the reaction scheme shown in Figure 1. In Figure 1, aldehyde (1) and ketone (2) undergo a Claisen-Schmidt aldol condensation upon treatment with potassium hydroxide in methanol according 25 to standard methods to provide compound (3). Treatment of compound (3) with pinacol (bromoalkyl)boronate in the presence of sodium hydride in THF

- 5  
general Formula II:
- 6  
In another embodiment, this invention relates to compounds of the  
7 compound (4).  
8 followed by deprotection under alkaline conditions provides the desired  
9 followed by deprotection under alkaline conditions provides the desired  
10 Figure 2, Ketone (5) and aldehyde (6) undergo a Claisen-Schmidt aldol  
11 condensation upon treatment with potassium hydroxide in methanol according  
12 to standard methods to provide compound (7). Treatment of compound (7)  
13 with pinacol (bromoalkyl)boronate in the presence of sodium hydride in THF,  
14 followed by deprotection under alkaline conditions provides the desired  
15 Figure 3 shows another general reaction scheme for the syntheses of  
compounds (14) and (15), which are also based upon a chemical structure II.  
According to Figure 3, aldehyde (9) and ketone (10) undergo a Claisen-  
Schmidt aldol condensation upon treatment with potassium hydroxide in  
methanol according to standard methods to provide compound (11).  
Compound (11) is converted to the acid chloride (12) by treating with thionyl  
chloride. Treatment of the acid chloride (12) with pinacol  
bis(trimethylsilyl)aminoalkylboronate (13) provides compound (14). Pinacol  
bis(trimethylsilyl)aminoalkylboronate (13) can be easily prepared as shown in  
Figure 3. Alternatively, treatment of compound (12) with an alkylaminoboronic  
acid provides compound (15).




16

17 In another embodiment, this invention relates to compounds of the  
18 compound (4).

19 followed by deprotection under alkaline conditions provides the desired  
20 followed by deprotection under alkaline conditions provides the desired  
21

In another embodiment, this invention relates to compounds of the general Formula III:



- 5 where Ar is as defined above and R<sup>4</sup> is H, an amine protecting group, Z<sub>n</sub>-OR<sup>1</sup>, Z<sub>n</sub>-SR<sup>1</sup>, Z<sub>n</sub>-R<sup>1</sup>, Z<sub>n</sub>-NR<sup>1</sup>(C=O)R<sup>1</sup>, Z<sub>n</sub>-C=OR<sup>1</sup>, Z<sub>n</sub>-OC(=O)R<sup>1</sup>, Z<sub>n</sub>-C(=O)OR<sup>1</sup>, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z<sub>n</sub>-cy cloalkyl, Z<sub>n</sub>-heterocycloalkyl, Z<sub>n</sub>-Ar or Z<sub>n</sub>-heteroaryl, wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl,
- 10 heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z<sub>n</sub>-cycloalkyl, Z<sub>n</sub>-heterocycloalkyl, Z<sub>n</sub>-Ar or Z<sub>n</sub>-heteroaryl may be substituted or unsubstituted, and where Z<sub>n</sub>, R<sup>1</sup> and n are as defined above.

Figure 4 shows a general reaction scheme for the synthesis of chalcone compound (19) based upon structure III. For example, reacting 1-aryl-2-propynone (16) with lithium chloride in acetic acid at room temperature provides 3-chloro-1-arylpropenone (17). Treatment of compound (17) with an arylaminoboronic acid (18) in the presence of triethylamine provides compound (19).

It is important to note that the methods of synthesizing the disclosed compounds are general examples, and one of ordinary skill may readily determine or provide alternative syntheses for producing compounds according to the present invention without engaging in undue experimentation. Using the general and specific synthetic methodologies described herein, a number of the chemical compounds as set forth in Table 1 were synthesized.

The compounds of the present invention are useful for treating or preventing benign and malignant tumors, including various cancers such as,

- 5 cervical, anal and oral cancers, stomach, colon, bladder, rectal, liver, pancreatic, lung, breast, cervix uteri, corpus uteri, ovary, prostate, testis, renal, brain/cns (e.g., gliomas), head and neck, eye or ocular, throat, skin carcinomas, small cell lung cancer, mouth/pharynx, esophagogastric, larynx, kidney and lymphoma, among others. In addition, conditions such as neurofibromatosis, tuberous sclerosis (each of which conditions produces benign tumors of the skin), hemangiomas and lymphangiogenesis, among others, may be treated effectively with compounds according to the present invention.
- 10 Methods of treating tumors and/or cancer according to the present invention comprise administering to a patient in need thereof an effective amount of one or more compounds according to the present invention or a pharmaceutical composition acceptable salt or *in vivo* deliverable prodrug thereof.
- 15 The invention also features methods of combination therapy, such as a method for treating cancer, wherein the above methods further include providing radiation therapy or chemotherapy, for example, with mitotic inhibitors such as taxane or a vinca alkaloid. Examples of mitotic inhibitors include paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine, and vinflunine. Other therapeutic combinations include a MEK inhibitor of the 20 inventors and an anticancer agent such as cisplatin, 5-fluorouracil or 5-fluoro-2-(1H,3H)-pyrimidinedione (5FU), flutamide, and gemcitabine. The 25 inventors skilled in the art to assess the anti-tumor and anti-cancer activity of those compounds according to the present invention. Any of these methods can be used to evaluate the activity of the compounds disclosed herein. One
- 30 Numerous biological assays have been used and are accepted by the patient.

- common method of assessing activity is through the use of test panels of cancer cell lines. These tests evaluate the *in vitro* anti-cancer activity of particular compounds in cancer cell lines, and provide predictive data with respect to the use of tested compounds *in vivo*. Other assays include *in vivo*
- 5 evaluations of the compound's effect on human or in an appropriate animal model, for example, using mouse tumor cells implanted into or grafted onto mice or in other appropriate animal models.

In the case of testing the anti-cancer activity of compounds according to the present invention, an assay based on human breast cancer MDA-MB-10 231 (estrogen receptor negative) and wtMCF7 (estrogen receptor positive) cells may be employed as described in Example 2. In this assay, cells are seeded onto a 96-well plate and treated with a compound according to the present invention at a known concentration. The cell numbers are counted and compared against controls. Percent inhibition is readily determined from 15 the data obtained. Other methods known in the art may also be used without undue experimentation to assay the anti-cancer activity of the disclosed compounds.

Therapeutically effective amounts of the compounds of the invention may also be used to treat diseases mediated by expression of MDM2. An 20 "effective amount" is intended to mean that amount of compound that, when administered to a mammal in need of such treatment, is sufficient to inhibit or attenuate expression of MDM2. Thus, for example, a therapeutically effective amount of a compound selected from Formulas I-III, or a salt, active metabolite or prodrug thereof, is a quantity sufficient to modulate, regulate, or 25 inhibit expression of MDM2.

The amount of a given agent that will correspond to such an amount will vary depending upon factors such as the particular compound, disease condition and its severity, the identity (e. g., weight) of the mammal in need of treatment, but can nevertheless be routinely determined by one skilled in the 30 art. "Treating" is intended to mean at least the mitigation of a disease

- 30 rendering the compositions of the present invention unstable or compromising  
 providing numerous formulations for a particular route of administration without  
 the art may modify the formulations within the teachings of the specification to  
 are preferably administered in sterile saline. Of course, one of ordinary skill in  
 including an eye or ocular route, intravenous and intramuscular formulations  
 intramuscular, transdermal, buccal, subcutaneous, suppository or other route,  
 other formulations may be administered via a topical, parenteral, intravenous,  
 admixtable form, but for treatment of a number of conditions, a number of  
 general, it is preferable to administer the pharmaceutical composition in orally  
 admixed with a pharmaceutically acceptable carrier, excipient or additive. In  
 compound according to the present invention is formulated preferably in  
 in the pharmaceutical aspect according to the present invention, the  
 intrabuccal, transdermal and in suppository form.  
 parenteral including intravenous, intramuscular, eye or ocular, intraperitoneal,  
 for all routes of administration including for example, oral, topical and  
 15 The compounds of this invention may be incorporated into formulations  
 pharmaceutically acceptable diluent or carrier.  
 there is provided a pharmaceutical composition that comprises a compound of  
 the Formula I-III, or a pharmaceutically acceptable salt or *in vivo* cleavable  
 10 is normally formulated in accordance with standard pharmaceutical practice  
 treatment (including prophylactic treatment) of mammals including humans,  
 acceptable salt or *in vivo* cleavable prodrug thereof, for the therapeutic  
 In order to use a compound of the Formula I-III, or a pharmaceutically  
 disease condition, and/or alleviating the disease condition.  
 when the mammal is found to be predisposed to having the disease condition  
 preventing the disease condition from occurring in a mammal, particularly  
 condition in a mammal, such as a human, and includes, but is not limited to,  
 5 but has not yet been diagnosed as having it; modulating and/or inhibiting the  
 when the mammal is found to be predisposed to having the disease condition  
 preventing the disease condition from occurring in a mammal, particularly  
 condition in a mammal, such as a human, and includes, but is not limited to,  
 10

their therapeutic activity. In particular, the modification of the present compounds to render them more soluble in water or other vehicle, for example, may be easily accomplished by minor modifications (salt formulation, esterification, etc.) which are well within the ordinary skill in the art. It is also well within the skill of those skilled in the art to modify the route of administration and dosage regimen of a particular compound in order to manage the pharmacokinetics of the present compounds for maximum beneficial effect to the patient.

The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, or intramuscular dosing or as a suppository for rectal dosing). For example, compositions intended for oral use may contain, for example, one or more coloring, sweetening, flavoring and/or preservative agents.

Suitable pharmaceutically-acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.

- Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or example heptadecethylenoxygen, or condensation products of ethylene condensation products of ethylene sorbitol monooctate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitol monooctate, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitan monooctate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), coloring agents, flavoring agents, and/or sweetening agents (such as sucrose, saccharine, or aspartame).
- Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above.

5 Additional excipients such as sweetening, flavoring and coloring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example 10 sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavoring and preservative agents.

15

Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also 20 contain a demulcent, preservative, flavoring and/or coloring agent.

The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile 25 injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.

Suppository formulations may be prepared by mixing the active 30 ingredient with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the

- rectangle to release the drug. Suitable excipients include, for example, cocoa butter and polyethylene glycols.
- Topical formulations, such as creams, ointments, gels and aqueous or oily solutions or suspensions, may generally be obtained by formulating an active ingredient with a conventional, topically acceptable, vehicle or diluent using conventional procedures well known in the art.
- Topical formulations, such as creams,ointments, gels and aqueous or oily solutions or suspensions, may generally be obtained by formulating an active ingredient with a conventional, topically acceptable, vehicle or diluent using conventional procedures well known in the art.
- Compositions for administration by insufflation may be in the form of a fine ly divided powder containing particles of average diameter of, for example, 30 µm or much less, the powder itself comprising either active ingredient alone or diluted with one or more physiologically acceptable carriers such as lactose. The powder for insufflation is then contained in a capsule containing, for example, 1 to 50 mg of active ingredient for use with a turbo-cone.
- Inhaler device, such as is used for insufflation of the known salt sodium cromoglycate.
- Compositions for administration by inhalation may be in the form of a conventional pressurized aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets.
- Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.
- For further information on formulations, see Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Cornwall Hansch; Chalmers et al Editorial Board), Pergamon Press 1990, which is specifically incorporated herein by reference.
- The amount of a compound of this invention that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration.
- For example, a formulation intended for oral administration to humans will contain, for example, from 0.5 mg to 2 g of active agent compound.
- may contain, for example, from 0.5 mg to 2 g of active agent compound.
- 25
- 20
- 15
- 10
- 5

with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient. For further information on routes of administration and dosage regimes, see Chapter 25.3 in Volume 5 of *Comprehensive Medicinal Chemistry* (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990, which is specifically incorporated herein by reference.

The size of the dose for therapeutic or prophylactic purposes of a compound of Formula I-III will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.

In one aspect of this invention, the compounds of this invention or pharmaceutical salts or prodrugs thereof may be formulated into pharmaceutical compositions for administration to animals or humans to treat or prevent solid tumors or cancer.

## EXAMPLES

In order to illustrate the invention, the following examples are included. However, it is to be understood that these examples do not limit the invention and are only meant to suggest a method of practicing the invention. Persons skilled in the art will recognize that the chemical reactions described may be readily adapted to prepare a number of other boronic chalcones of the invention, and alternative methods for preparing the compounds of this invention are deemed to be within the scope of this invention. For example, the synthesis of non-exemplified compounds according to the invention may be successfully performed by modifications apparent to those skilled in the art, e.g., by appropriately protecting interfering groups, by utilizing other suitable reagents known in the art other than those described, and/or by making routine modifications of reaction conditions. Alternatively, other reactions disclosed herein or known in the art will be recognized as having applicability for preparing other compounds of the invention.

<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 7.59 (d,  $J = 8$  Hz, 1H), 7.69–7.73 (m, 2H), 7.77 (d,  $J = 8$  Hz, 2H), m.p. 267–268° C; mass spectrum (EI mode):  $m/z = 11$  (1H), 8.07 (d,  $J = 8$  Hz, 2H);  $m/z = 267\text{--}268$ .

<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 7.59 (d,  $J = 8$  Hz, 1H), 7.69–7.73 (m, 2H), 7.79 (d,  $J = 16$  Hz, 1H), 7.83 (d,  $J = 15.6$  Hz, 1H), 7.98 (d,  $J = 2$  Hz, 1H), 8.05 (d,  $J = 8$  Hz, 2H);  $m/z = 268\text{--}270$ .

<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 7.53 (d,  $J = 8.4$  Hz, 2H), 7.71 (d,  $J = 16$  Hz, 1H), 7.79 (d,  $J = 16$  Hz, 1H), 7.82 (m, 4H), 8.05 (d,  $J = 8$  Hz, 2H);  $m/z = 377$  [M]<sup>+</sup>, 378 [M]<sup>+</sup>.

### Compound 3b

#### Example 3

(<sup>11</sup>B): yield 86 %.

<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 7.53 (d,  $J = 8.4$  Hz, 2H), 7.71 (d,  $J = 16$  Hz, 1H), 7.79 (d,  $J = 16$  Hz, 1H), 7.82 (m, 4H), 8.05 (d,  $J = 8$  Hz, 2H);  $m/z = 268\text{--}270$ .

To a solution of an acceptophenone ( $1.0 \text{ mL/mol}$ ) was added an aldehyde ( $1.5 \text{ equiv}$ ) followed by an aqueous solution of KOH (50%,  $1 \text{ mL/mol}$  of acceptophenone). The mixture was heated at 70° C for 4–6 hours and monitored by TLC. Water ( $20 \text{ mL}$ ) was then added, the methanol was evaporated, and the solution was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was dried and evaporated to dryness, then purified by recrystallization with methanol–water to afford the desired chlorocone.

### Compound 3a

#### Example 2

<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 7.53 (d,  $J = 8.4$  Hz, 2H), 7.71 (d,  $J = 16$  Hz, 1H), 7.79 (d,  $J = 16$  Hz, 1H), 7.82 (m, 4H), 8.05 (d,  $J = 8$  Hz, 2H);  $m/z = 377$  [M]<sup>+</sup>, 378 [M]<sup>+</sup>.

To a solution of an acceptophenone in methanol ( $1.0 \text{ mL/mol}$ ) was added an aldehyde ( $1.5 \text{ equiv}$ ) followed by an aqueous solution of KOH (50%,  $1 \text{ mL/mol}$  of acceptophenone). The mixture was heated at 70° C for 4–6 hours and monitored by TLC. Water ( $20 \text{ mL/mol}$ ) was then added, the methanol was evaporated, and the solution was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was dried and evaporated to dryness, then purified by recrystallization with methanol–water to afford the desired chlorocone.

### General procedure for the preparation of boronic chalcogen analogs

#### Example 1

In the examples below, unless otherwise indicated all temperatures are set forth in degrees Celsius. Reagents were purchased from commercial suppliers such as Aldrich Chemical Co., Lancaster, TCI or Maybridge, and used without further purification unless otherwise indicated. The reactions set forth were generally under a positive pressure of nitrogen or argon or below done generally under a positive pressure of nitrogen or argon or flasks were typically fitted with rubber septa for the introduction of substrates with a drying tube (unless otherwise stated) in anhydrous solvents. The reaction flasks were typically fitted with rubber septa for the introduction of substrates and reagents via syringes. Glassware was oven dried and/or heat dried.

10

15

25

319 [M]<sup>+</sup> (<sup>35</sup>Cl<sup>35</sup>Cl<sup>10</sup>B), 320 [M]<sup>+</sup> (<sup>35</sup>Cl<sup>35</sup>Cl<sup>11</sup>B), 321 [M]<sup>+</sup> (<sup>35</sup>Cl<sup>37</sup>Cl<sup>10</sup>B), 322 [M]<sup>+</sup> (<sup>35</sup>Cl<sup>37</sup>Cl<sup>11</sup>B), 323 [M]<sup>+</sup> (<sup>37</sup>Cl<sup>37</sup>Cl<sup>10</sup>B), 324 [M]<sup>+</sup> (<sup>37</sup>Cl<sup>37</sup>Cl<sup>11</sup>B); Yield 80 %.

#### Example 4

##### Compound 3c

5         <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 7.14 (d, *J* = 8.4 Hz, 1H), 7.66 (d, *J* = 8 Hz, 2H), 7.68 (d, *J* = 15.2 Hz, 1H), 7.72 (d, *J* = 15.2 Hz, 1H), 7.77 (d, *J* = 8.4 Hz, 1H), 7.86 (d, *J* = 2.4 Hz, 1H), 8.05 (d, *J* = 8 Hz, 2H); m.p. 242-243° C; mass spectrum (EI mode): *m/z* = 303 [M]<sup>+</sup> (<sup>35</sup>Cl<sup>10</sup>B), 304 [M]<sup>+</sup> (<sup>35</sup>Cl<sup>11</sup>B), 305 [M]<sup>+</sup> (<sup>37</sup>Cl<sup>10</sup>B), 306 [M]<sup>+</sup> (<sup>37</sup>Cl<sup>11</sup>B); Yield 90 %.

10                  Example 5  
Compound 3d

15         <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 7.15 (dd, *J* = 8.4 Hz, 8.8Hz, 1H), 7.61 (m, 2H), 7.51 (m, 1H), 7.63 (d, *J* = 15.6 Hz, 1H), 7.73 (d, *J* = 15.6 Hz, 1H), 7.77 (m, 1H), 8.05 (d, *J* = 7.8 Hz, 2H); m.p. 254-255° C; mass spectrum (EI mode): *m/z* = 287 [M]<sup>+</sup> (<sup>10</sup>B), 288 [M]<sup>+</sup> (<sup>11</sup>B); Yield 85 %.

#### Example 6

##### Compound 3e

20         <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 7.12 (d, *J* = 8.4 Hz, 1H), 7.66 (d, *J* = 16 Hz, 1H), 7.71 (d, *J* = 16 Hz, 1H), 7.73 (m, 1H), 7.77 (d, *J* = 8 Hz, 2H), 8.01 (d, *J* = 2 Hz, 1H), 8.05 (d, *J* = 8Hz, 2H); m.p. 163-164° C; mass spectrum (EI mode): *m/z* = 347 [M]<sup>+</sup> (<sup>79</sup>Br<sup>10</sup>B), 348 [M]<sup>+</sup> (<sup>79</sup>Br<sup>11</sup>B), 349 [M]<sup>+</sup> (<sup>81</sup>Br<sup>10</sup>B), 350 [M]<sup>+</sup> (<sup>81</sup>Br<sup>11</sup>B); Yield 89 %.

#### Example 7

##### Compound 3f

25         <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm): 4.81 (s, 2H), 7.04 (d, *J* = 8.8 Hz, 2H), 7.62 (d, *J* = 15.6 Hz, 1H), 7.66 (d, *J* = 8 Hz, 2H), 7.8 (d, *J* = 8.4 Hz, 2H),

283-285<sup>a</sup> C; mass spectrum (EI mode):  $m/z = 319$  [M]<sup>+</sup>, (<sup>35</sup>Cl<sub>35</sub>Cl<sub>10</sub>B), 320 [M]<sup>+</sup>, 25  
 15.6 Hz, 1H), 7.99 (dd,  $J = 8.2$  Hz, 1.6 Hz, 1H), 8.19 (d,  $J = 1.6$  Hz, 1H); m.p.  
<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>O) δ (ppm): 7.67-7.741 (m, 6H), 7.82 (d,  $J =$

Compound 8  
Example 11

mode):  $m/z = 407$  [M]<sup>+</sup>, (<sup>10</sup>B), 408 [M]<sup>+</sup>, (<sup>11</sup>B); yield 45 %.  
 20  
 1H), 7.80 (d,  $J = 15.6$  Hz, 1H), 8.05 (d,  $J = 8.4$  Hz, 2H); mass spectrum (EI  
 1H), 7.12 (d,  $J = 8.8$  Hz, 2H), 7.5 (d,  $J = 8.4$  Hz, 2H), 7.65 (d,  $J = 15.6$  Hz,  
 2H), 7.01 (d,  $J = 8.8$  Hz, 1H).  
<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>O) δ (ppm): 3.41 (s, 2H), 7.01 (d,  $J = 8.8$  Hz,

Compound 7  
Example 10

mode):  $m/z = 350$  [M]<sup>+</sup>; yield 98 %.  
 15  
 8 Hz, 2H), 8.0 (d,  $J = 8.4$  Hz, 2H); m.p. 215-216<sup>a</sup> C; mass spectrum (EI  
 = 8.4 Hz, 2H), 7.52 (d,  $J = 15.6$  Hz, 1H), 7.71 (d,  $J = 15.6$  Hz, 1H), 7.76 (d,  $J =$   
<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>O) δ (ppm): 6.93 (d,  $J = 8$  Hz, 2H), 7.36 (d,  $J$

Compound 6  
Example 9

$m/z = 350$  [M]<sup>+</sup>, (<sup>35</sup>Cl<sub>35</sub>Cl), 352 [M]<sup>+</sup>, (<sup>35</sup>Cl<sub>37</sub>Cl), 354 [M]<sup>+</sup>, (<sup>37</sup>Cl<sub>37</sub>Cl); yield 95 %.  
 10  
 2 Hz, 1H), 8.12 (d,  $J = 9.2$  Hz, 2H); m.p. 186-187<sup>a</sup> C; mass spectrum (EI mode):  
 2H), 7.58 (d,  $J = 8.8$  Hz, 1H), 7.67 (m, 2H), 7.82 (d,  $J = 15.6$  Hz, 1H), 7.95 (d,  $J =$   
<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>O) δ (ppm): 4.91 (s, 2H), 7.07 (d,  $J = 9.2$  Hz,  
 5

Compound 5a  
Example 8

spectrum (EI mode):  $m/z = 408$  [M]<sup>+</sup>; yield 90 %.  
 281-282<sup>a</sup> C; mass  
 7.97 (d,  $J = 15.6$  Hz, 1H), 8.13 (d,  $J = 8.8$  Hz, 2H); m.p.

( $^{35}\text{Cl}^{35}\text{Cl}^{11}\text{B}$ ), 321 [M] $^{+•}$  ( $^{35}\text{Cl}^{37}\text{Cl}^{10}\text{B}$ ), 322 [M] $^{+•}$  ( $^{35}\text{Cl}^{37}\text{Cl}^{11}\text{B}$ ), 323 [M] $^{+•}$  ( $^{37}\text{Cl}^{37}\text{Cl}^{10}\text{B}$ ), 324 [M] $^{+•}$  ( $^{37}\text{Cl}^{37}\text{Cl}^{11}\text{B}$ ); Yield 68 %.

Example 12

Compound 9

5          $^1\text{H}$  NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  (ppm): 4.79 (s, 2H), 7.02 (d,  $J$  = 8.8 Hz, 2H), 7.76 (d,  $J$  = 15.6 Hz, 1H), 7.83-7.91 (m, 4H), 8.11 (dd,  $J$  = 8 Hz, 2Hz, 1H), 8.4 (d,  $J$  = 2 Hz, 1H); m.p. 209-210° C; mass spectrum (EI mode):  $m/z$  = 350 [M] $^{+•}$  ( $^{35}\text{Cl}^{35}\text{Cl}$ ), 352 [M] $^{+•}$  ( $^{35}\text{Cl}^{37}\text{Cl}$ ), 354 [M] $^{+•}$  ( $^{37}\text{Cl}^{37}\text{Cl}$ ); Yield 78 %.

Example 13

Compound 11

10          $^1\text{H}$  NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  (ppm): 6.31 (dd,  $J$  = 2.4 Hz, 3.2 Hz, 1H), 7.15 (d,  $J$  = 2.4 Hz, 1H), 7.25 (d,  $J$  = 3.2 Hz, 1H), 7.55 (d,  $J$  = 15.6 Hz, 1H), 7.66 (m, 2H), 7.7 (d,  $J$  = 15.6 Hz, 1H), 7.79 (m, 2H); m.p. 229-231° C; mass spectrum (EI mode):  $m/z$  = 240 [M] $^{+•}$  ( $^{10}\text{B}$ ), 241 [M] $^{+•}$  ( $^{11}\text{B}$ ); Yield 60 %.

| Compound | Molecular formula                                  | Calculated |      | Found |       | Example 12 | Cytotoxicity of boronic chalcone analogs |
|----------|--|------------|------|-------|-------|------------|--|
|          |  | C          | H    | C     | H     |            |  |
| 3a       | $\text{C}_{15}\text{H}_{12}\text{BIO}_3$           | 47.67      | 3.20 | -     | 47.72 | 3.22       | -  |
| 3b       | $\text{C}_{15}\text{H}_{11}\text{BCl}_2\text{O}_3$ | 56.13      | 3.45 | -     | 56.23 | 3.52       | -  |
| 3c       | $\text{C}_{15}\text{H}_{11}\text{BClFO}$           | 59.16      | 3.64 | -     | 59.40 | 3.71       | -  |
| 3d       | $\text{C}_{15}\text{H}_{11}\text{BF}_2\text{O}_3$  | 62.54      | 3.85 | -     | 62.42 | 3.92       | -  |
| 3e       | $\text{C}_{15}\text{H}_{11}\text{BBFO}$            | 51.63      | 3.18 | -     | 51.52 | 3.24       | -  |
| 3f       | $\text{C}_{17}\text{H}_{13}\text{IO}_4$            | 50.02      | 3.21 | -     | 50.16 | 3.29       | -  |
| 3g       | $\text{C}_{17}\text{H}_{12}\text{Cl}_2\text{O}_4$  | 58.14      | 3.44 | -     | 57.98 | 3.50       | -  |
| 6        | $\text{C}_{15}\text{H}_{11}\text{IO}_2$            | 51.45      | 3.17 | -     | 51.50 | 3.22       | -  |
| 7        | $\text{C}_{16}\text{H}_{11}\text{BIO}_4$           | 47.10      | 3.46 | -     | 47.22 | 3.51       | -  |
| 8        | $\text{C}_{15}\text{H}_{11}\text{BCl}_2\text{O}_3$ | 56.13      | 3.45 | -     | 56.28 | 3.50       | -  |
| 9        | $\text{C}_{17}\text{H}_{12}\text{Cl}_2\text{O}_4$  | 58.14      | 3.44 | -     | 58.22 | 3.42       | -  |
| 10       | $\text{C}_{13}\text{H}_{11}\text{NO}$              | 79.16      | 5.62 | 7.10  | 79.34 | 5.68       | 7.12                                     |
| 11       | $\text{C}_{13}\text{H}_{12}\text{BNO}_3$           | 64.77      | 5.02 | 5.81  | 64.86 | 5.10       | 5.89                                     |

Table 2. Elemental analytical data of the chalcone analogs


supplemented with 5% fetal bovine serum and 2 mM glutamine. Each cell line used has unique growth characteristics spanning the spectrum of tumor invasiveness, differentiation and estrogen dependence. Normal breast epithelial cell lines, MCF-10A and MCF-12A, were maintained in 5% and 10%  
5 horse serum in DMEM:Ham's F12 media, respectively, supplemented with 2 mM glutamine, 100 units/mL penicillin/streptomycin, 0.02 µg/mL EGF, 0.01 mg/mL insulin, and 0.1 µg/mL cholera toxin.

Cells were incubated at 37° C in a 5% CO<sub>2</sub> atmosphere. The MTT colorimetric assay was used to determine growth inhibition (Mosmann, T., J.  
10 *Immunol. Methods*, 1983, 65, 55-63). Cells were plated in 96-well plates and allowed to attach for 24 hours. Chalcone derivatives based on compounds 20 and 21 below were dissolved in DMSO at 10 mM concentrations. Cells were exposed in quadruplicate well to chalcone concentrations of 0.5-100 µM for 96 hours. After 96 hours the media was aspirated, and 100 µL of 1 mg/mL MTT  
15 solution (Sigma Chemical Co.) diluted in serum free media was added to each well. After 4 hours of incubation, the MTT solution was removed and 200 µL of 1:1 (v/v) solution of DMSO: ethanol was added to each well to dissolve formazan crystals. The absorbance at A<sub>540nm</sub> was determined on a plate reader. IC<sub>50</sub> values were determined from log plots of percent of control vs.  
20 concentration. Each compound was assayed twice in quadruplicate. Analogs 3g and 9 have been previously described (Stoll R., et al., *supra*; Kussie, P. H., et al., *supra*) and were included for comparative purposes.

inhibited but normal breast epithelial cells are significantly less inhibited.  
 differentially inhibit growth such that human breast cancer cell lines are  
 able to chalcone derivatives. Of particular interest are compounds able to  
 IC<sub>50</sub> values used to determine growth inhibition in the presence of 10

| Compound | A  | B  | C  | 9 | Cl | OCH <sub>2</sub> COOH              |
|----------|----|----|----|---|----|------------------------------------|
|          | CI | CI | Cl | 8 | Cl | (B(OH) <sub>2</sub> ) <sub>2</sub> |


21



5

| Compound | A  | B  | C                  | 7  | H                                  | OCH <sub>2</sub> (OH) <sub>2</sub> |
|----------|----|----|--------------------|----|------------------------------------|------------------------------------|
|          | CI | CI | Cl                 | 6  | H                                  | OH                                 |
| 3g       | CI | CI | Cl                 | 3f | H                                  | OCH <sub>2</sub> COOH              |
| 3f       | I  | I  | Cl                 | 3e | Br                                 | (B(OH) <sub>2</sub> ) <sub>2</sub> |
| 3e       | F  | F  | Br                 | 3d | F                                  | (B(OH) <sub>2</sub> ) <sub>2</sub> |
| 3d       | F  | F  | Cl                 | 3c | (B(OH) <sub>2</sub> ) <sub>2</sub> | (B(OH) <sub>2</sub> ) <sub>2</sub> |
| 3c       | Cl | Cl | Cl                 | 3b | Cl                                 | (B(OH) <sub>2</sub> ) <sub>2</sub> |
| 3b       | I  | H  | B(OH) <sub>2</sub> | 3a | H                                  | B(OH) <sub>2</sub>                 |
| 3a       |    |    |                    |    |                                    |                                    |

20



Compound 3a, 3d, 3e, 7, 8, 10 and 11 are 5-10 fold more toxic to human breast cancer cell lines compared to normal breast epithelial cell lines (Table 1). In the presence of these compounds, cell growth in the human breast cancer cell lines MDA-MB-435, MDA-MB-231, and wt-MCF7 is inhibited,  
 5 indicated by the range of low IC<sub>50</sub> values from 3.5 to 23. Cell growth in the normal breast epithelial cell lines MCF-10A and MCF-12A is less inhibited, shown by higher IC<sub>50</sub> values ranging from 11 to 75.

Table 1. Chalcones inhibit growth of human breast cell lines<sup>a</sup>

| Compound | MDA-MB-435<br>IC <sub>50</sub> | MDA-MB-231<br>IC <sub>50</sub> | Wt-MCF7<br>IC <sub>50</sub> | MCF-10A<br>IC <sub>50</sub> | MCF-12A<br>IC <sub>50</sub> |
|----------|--------------------------------|--------------------------------|-----------------------------|-----------------------------|-----------------------------|
| 3a       | 10                             | 8.8                            | 7.0                         | 75                          | 63                          |
| 3b       | 3.5                            | 9.5                            | 5.0                         | 18                          | 11                          |
| 3c       | 16                             | 8.5                            | 6.0                         | 25                          | 22                          |
| 3d       | 8.8                            | 8.8                            | 7.8                         | 18                          | 39                          |
| 3e       | 8.8                            | 9.5                            | 8.5                         | 17                          | 38                          |
| 3f       | 18                             | 44                             | 9                           | 44                          | 38                          |
| 3g       | 9                              | 9                              | 13                          | 13                          | 15                          |
| 6        | 4.5                            | 8                              | 7                           | 15                          | 30                          |
| 7        | 18                             | 11                             | 9.5                         | 38                          | 100                         |
| 8        | 4                              | 8                              | 5.5                         | 18                          | 15                          |
| 9        | 13                             | 18                             | 15                          | 12                          | 28                          |
| 10       | 15                             | 15                             | 9                           | 63                          | 38                          |
| 11       | 15                             | 23                             | 19                          | 38                          | 60                          |

<sup>a</sup> IC<sub>50</sub> values expressed in μM; see biology section for details of the MTT assay.  
 10

The foregoing description is considered as illustrative only of the principles of the invention. Further, since numerous modifications and changes will be readily apparent to those skilled in the art, it is not desired to limit the invention to the exact construction and process shown as described


above. Accordingly, all suitable modifications and equivalents may be resorted to falling within the scope of the invention as defined by the claims that follow.

The words "comprise", "comprising", "include", "including", and "includes" when used in this specification and in the following claims are intended to specify the presence of stated features, integers, components, or structures, but they do not preclude the presence or addition of one or more other steps, but they do not preclude the presence or addition of one or more other features, integers, components, steps, or groups thereof.

## CLAIMS

What is claimed is:

1. A compound including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, said compound  
5 having the Formula (I):



where:

- Ar is aryl or heteroaryl, each of which may be substituted or  
10 unsubstituted;
- W is H,  $Z_n$ -F,  $Z_n$ -Cl,  $Z_n$ -Br,  $Z_n$ -I,  $Z_n$ -CF<sub>3</sub>,  $Z_n$ -NO<sub>2</sub>,  $Z_n$ -OR<sup>1</sup>,  $Z_n$ -NR<sup>1</sup>R<sup>2</sup>,  $Z_n$ -COOR<sup>1</sup>,  $Z_n$ -SR<sup>1</sup>,  $Z_n$ -(C=O)R<sup>1</sup>,  $Z_n$ -O(C=O)R<sup>1</sup>,  $Z_n$ -NR<sup>1</sup>(C=O)R<sup>1</sup>,  $Z_n$ -(C=O)NR<sup>1</sup>, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl,  $Z_n$ -heteroaryl, or  $Z_n$ -heteroalkyl, wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl,  $Z_n$ -Ar or  $Z_n$ -heteroaryl may be substituted or unsubstituted;  
15
- X is  $Z_n$ ,  $Z_n$ -O,  $Z_n$ -S,  $Z_n$ -NR<sup>1</sup>,  $Z_n$ -NR<sup>1</sup>(C=O),  $Z_n$ -C=O,  $Z_n$ -OC(=O), or  $Z_n$ -C(=O)O;  
20
- $R^1$  and  $R^2$  are independently H, an amine protecting group, an alcohol protecting group, an acid protecting group, a sulfur protecting group, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl,  $Z_n$ -Ar or  $Z_n$ -heteroaryl, wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy,  
25


hetorokacyd or  $Z_1$ -hetorokacydallyl,  $Z_1$ -Ar or  $Z_1$ -heteroaryl may be substituted or unsubstituted, or  $R_1$  together with  $R_2$  and N forms a saturated or partially unsaturated heterocyclic ring having 1 or more heteroatoms in said ring, wherein said heterocyclic ring may be substituted or unsubstituted or fused to an aromatic ring; heterocycle may be substituted or unsubstituted and wherein said Z is an alkylene having at least 1 carbon, or an alkenylene or alkynylene each having at least 2 carbons, wherein said alkylene, alkynylene, or alkyne may be substituted or unsubstituted; and n is zero or any integer.

The compound of claim 1 having the structure


The chemical structure shows a benzene ring substituted at the para position with a group consisting of a phenyl ring attached to a central carbon atom. This central carbon is bonded to a  $\text{B}(\text{OH})_2$  group, a double-bonded vinyl group ( $=\text{CH}_2$ ), and a single-bonded phenyl ring. The phenyl ring on the central carbon is further substituted at the para position with a  $\text{Cl}$  atom and at the meta position with a  $\text{F}$  atom.

The compound of claim 1 having the structure

5. The compound of claim 1 having the structure




6. The compound of claim 1 having the structure




5


7. The compound of claim 1 having the structure



8. The compound of claim 1 having the structure



9. The compound of claim 1 having the structure



10

۴۱

or R<sup>1</sup> together with R<sup>2</sup> and N forms a saturated or partially unsaturated heterocycle ring having 1 or more heteroatoms in said ring, wherein said heterocycle may be substituted or unsubstituted and wherein said heterocycle may be fused to an aromatic ring;


5 R<sup>3</sup> is an electron-withdrawing moiety;

Z is an alkylene having at least 1 carbon, or an alkenylene or alkynylene each having at least 2 carbons, wherein said alkylene, alkenylene, or alkynylene may be substituted or unsubstituted; and

n = zero or any integer.

10 11. The compound of claim 10, wherein R<sup>3</sup> is fluoro, chloro, bromo, iodo, NO<sub>2</sub>, NH<sub>2</sub>, CN, SO<sub>2</sub>R<sup>1</sup>, SO<sub>2</sub>Ar, COOH, OAr, COOR<sup>1</sup>, OR<sup>1</sup>, COR<sup>1</sup>, SH, SR<sup>1</sup>, OH, CF<sub>3</sub>, Ar, alkenyl, alkynyl or allyl, wherein said OAr, Ar, alkenyl, alkynyl and allyl may be optionally unsubstituted or substituted with an electron withdrawing moiety

15 12. A compound including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, said compound having the Formula (III):



III

20 where

Ar is aryl or heteroaryl, each of which may be substituted or unsubstituted;

25 R<sup>4</sup> is H, an amine protecting group, Z<sub>n</sub>-OR<sup>1</sup>, Z<sub>n</sub>-SR<sup>1</sup>, Z<sub>n</sub>-NR<sup>1</sup>, Z<sub>n</sub>-NR<sup>1</sup>(C=O)R<sup>1</sup>, Z<sub>n</sub>-C=OR<sup>1</sup>, Z<sub>n</sub>-OC(=O)R<sup>1</sup>, Z<sub>n</sub>-C(=O)OR<sup>1</sup>, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl,

(C=O)NR<sup>1</sup>, alkyl, allyl, alkenyl, alkyndyl, heteroalkyl, heteroallyl,  
 COOR<sup>1</sup>, Z<sup>m</sup>-SR<sup>1</sup>, Z<sup>m</sup>-(C=O)R<sup>1</sup>, Z<sup>m</sup>-O(C=O)R<sup>1</sup>, Z<sup>m</sup>-NR<sup>1</sup>(C=O)R<sup>1</sup>, Z<sup>m</sup>-  
 W is H, Z<sup>m</sup>-F, Z<sup>m</sup>-Cl, Z<sup>m</sup>-Br, Z<sup>m</sup>-I, Z<sup>m</sup>-CF<sub>3</sub>, Z<sup>m</sup>-NO<sub>2</sub>, Z<sup>m</sup>-OR<sup>1</sup>, Z<sup>m</sup>-NR<sup>1</sup>R<sup>2</sup>, Z<sup>m</sup>-

25


unsubstituted;

Ar is aryl or heteroaryl, each of which may be substituted or

where

20

I



compound having the Formula (I):

thereof comprising admixing to said patient an effective amount of a  
 13. A method of treating a tumor or cancer in a patient in need

15

n is zero or any integer.

alkenylene, or alkynylene may be substituted or unsubstituted; and  
 alkenylene each having at least 2 carbons, wherein said alkenylene,  
 Z is an alkenylene having at least 1 carbon, or an alkenylene or  
 heteroaryl may be substituted or unsubstituted;

10

alkoxy, heteroalkoxy, Z<sup>n</sup>-cycloalkyl, Z<sup>n</sup>-heterocycloalkyl, or Z<sup>n</sup>-Ar or Z<sup>n</sup>-  
 alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroallyl,  
 heterocycloalkyl, Z<sup>n</sup>-Ar or Z<sup>n</sup>-heteroaryl, wherein said allyl, alkylnyl,  
 heteroalkenyl, heteroalkoxy, heteroalkyl, heteroallyl, heteroalkyl, heteroallyl,  
 R<sup>1</sup> is H, alkyl, allyl, alkenyl, alkyndyl, heteroalkyl, heteroallyl,  
 substituted or unsubstituted;

5

cycloalkyl, Z<sup>n</sup>-heterocycloalkyl, Z<sup>n</sup>-Ar or Z<sup>n</sup>-heteroaryl may be  
 heteroallyl, heteroalkenyl, heteroalkyl, alkoxy, heteroalkoxy, Z<sup>n</sup>-  
 heteroaryl, wherein said alkyl, allyl, alkenyl, alkyndyl, heteroalkyl,  
 heteroalkoxy, heteroalkoxy, Z<sup>n</sup>-cycloalkyl, Z<sup>n</sup>-heterocycloalkyl, Z<sup>n</sup>-Ar or Z<sup>n</sup>-

heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl,  $Z_n$ -Ar or  $Z_n$ -heteroaryl, wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl,  $Z_n$ -Ar or  $Z_n$ -heteroaryl may be substituted or unsubstituted;

5           X is  $Z_n$ ,  $Z_n$ -O,  $Z_n$ -S,  $Z_n$ -NR<sup>1</sup>,  $Z_n$ -NR<sup>1</sup>(C=O),  $Z_n$ -C=O,  $Z_n$ -OC(=O), or  $Z_n$ -C(=O)O;

R<sup>1</sup> and R<sup>2</sup> are independently H, an amine protecting group, an alcohol protecting group, an acid protecting group, a sulfur protecting group, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl,  $Z_n$ -Ar or  $Z_n$ -heteroaryl, wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl,  $Z_n$ -Ar or  $Z_n$ -heteroaryl may be substituted or unsubstituted,

10           or R<sup>1</sup> together with R<sup>2</sup> and N forms a saturated or partially unsaturated heterocycle ring having 1 or more heteroatoms in said ring, wherein said heterocycle may be substituted or unsubstituted and wherein said heterocycle may be fused to an aromatic ring;

15           Z is an alkylene having at least 1 carbon, or an alkenylene or alkynylene each having at least 2 carbons, wherein said alkylene, alkenylene, or alkynylene may be substituted or unsubstituted; and

n is zero or any integer.

14. The method of claim 13, wherein said tumor is selected from the group consisting of breast, cervical, stomach, colon, bladder, rectal, liver, pancreatic, lung, cervix uteri, corpus uteri, ovary, prostate, testis, renal, brain/cns, head, neck, throat, anal and oral cancers, eye or ocular cancer, skin melanoma, Ewing's Sarcoma, Kaposi's Sarcoma, basal cell carcinoma and squamous cell carcinoma, small cell lung cancer, mouth/pharynx,

hetereoalkyl, heteroallyl, heteroalkenyl, heteroallynyl, alkoxy, Z<sub>n</sub>-Ar or Z<sub>n</sub>-heteroaryl, wherein said alkoxy, Z<sub>n</sub>-Ar or Z<sub>n</sub>-heteroaryl, wherein said alkyl, allyl, alkenyl, alkyne, alkynyl, heteroalkenyl, heteroallyl, heteroallynyl, heteroalkoxy, Z<sub>n</sub>-cycloalkyl, Z<sub>n</sub>-hetereocycloalkyl, heteroalkenyl, alkenyl, alkynyl, alkynyl, heteroallyl, heteroalkenyl, protecting group, an acid protecting group, a sulfur protecting group, R<sub>1</sub> and R<sub>2</sub> are independently H, an amine protecting group, an alcohol

20 C(=O)O;  
X is Z<sub>n</sub>, Z<sub>n</sub>-O, Z<sub>n</sub>-S, Z<sub>n</sub>-NR<sub>1</sub>, Z<sub>n</sub>-NR<sub>1</sub>(C=O), Z<sub>n</sub>-C=O, Z<sub>n</sub>-OC(=O), or Z<sub>n</sub>-

Z<sub>n</sub>-heteroaryl may be substituted or unsubstituted;

15 Z<sub>n</sub>-heteroalkoxy, Z<sub>n</sub>-cycloalkyl, Z<sub>n</sub>-hetereocycloalkyl, Z<sub>n</sub>-Ar or alkoxyl, heteroalkoxy, Z<sub>n</sub>-Ar or Z<sub>n</sub>-heteroalkenyl, heteroallyl, heteroalkenyl, heteroallynyl, heteroalkenyl, alkynyl, heteroallyl, heteroallynyl, heteroalkenyl, heteroallyl, heteroallynyl, heteroalkenyl, heteroallyl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, (C=O)NR<sub>1</sub>, alkyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, COOR<sub>1</sub>, Z<sub>n</sub>-SR<sub>1</sub>, Z<sub>n</sub>-(C=O)R<sub>1</sub>, Z<sub>n</sub>-O(C=O)R<sub>1</sub>, Z<sub>n</sub>-NR<sub>1</sub>(C=O)R<sub>1</sub>, Z<sub>n</sub>-


W is H, Z<sub>n</sub>-F, Z<sub>n</sub>-Cl, Z<sub>n</sub>-Br, Z<sub>n</sub>-I, Z<sub>n</sub>-CF<sub>3</sub>, Z<sub>n</sub>-NO<sub>2</sub>, Z<sub>n</sub>-OR<sub>1</sub>, Z<sub>n</sub>-NR<sub>1</sub>R<sub>2</sub>, Z<sub>n</sub>-

10 unsubstituted;

Ar is aryl or heteroaryl, each of which may be substituted or

where

II



5 compound having the Formula (II):

thereof comprising admixing to said patient an effective amount of a therapeutic agent to treat a tumor or cancer in a patient in need

15. A method of treating a tumor or cancer in a patient in need acute myelogenous leukemia, esophageal, larynx, kidney and lymphoma, acute lymphocytic leukemia, and


heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl,  $Z_n$ -Ar or  $Z_n$ -heteroaryl may be substituted or unsubstituted,  
or  $R^1$  together with  $R^2$  and N forms a saturated or partially unsaturated heterocycle ring having 1 or more heteroatoms in said ring, wherein  
said heterocycle may be substituted or unsubstituted and wherein said heterocycle may be fused to an aromatic ring;

5            $R^3$  is an electron-withdrawing moiety;

10           Z is an alkylene having at least 1 carbon, or an alkenylene or alkynylene each having at least 2 carbons, wherein said alkylene, alkenylene, or alkynylene may be substituted or unsubstituted; and  
n = zero or any integer.

16.         The method of claim 15, wherein said tumor is selected from the group consisting of breast, cervical, stomach, colon, bladder, rectal, liver, pancreatic, lung, cervix uteri, corpus uteri, ovary, prostate, testis, renal, brain/cns, head, neck, throat, anal and oral cancers, eye or ocular cancer, skin melanoma, Ewing's Sarcoma, Kaposi's Sarcoma, basal cell carcinoma and squamous cell carcinoma, small cell lung cancer, mouth/pharynx, esophageal, larynx, kidney and lymphoma, acute lymphocytic leukemia, and acute myelogenous leukemia.

20         17.         A method of treating a tumor or cancer in a patient in need thereof comprising administering to said patient an effective amount of a compound having the Formula (III):



III

acute myelogenous leukemia.  
 esophagaea, larynx, kidney and lymphoma, acute lymphocytic leukemia, and  
 and squamous cell carcinoma, small cell lung cancer, mouth/pharynx,  
 skin melanoma, Ewing's Sarcoma, Kaposi's Sarcoma, basal cell carcinoma  
 brain/cns, head, neck, throat, anal and oral cancers, eye or ocular cancer,  
 pancreatic, lung, cervix uteri, corpus uteri, ovary, prostate, testis, renal,  
 group consisting of breast, cervical, stomach, colon, bladder, rectal, liver,  
 18. The method of claim 17, wherein said tumor is selected from the  
 acute myelogenous leukemia.


25  
 n is zero or any integer.  
 alkynylene, or alkynylene may be substituted or unsubstituted; and  
 alkynylene each having at least 2 carbons, wherein said alkynylene,  
 Z is an alkylene having at least 1 carbon, or an alkynylene or  
 heteroaryl may be substituted or unsubstituted;

15  
 alkoxyl, heteroalkoxy,  $Z_1$ -cyclalkyl,  $Z_1$ -heterocyclalkyl,  $Z_1$ -Ar or  $Z_1$ -  
 alkynyl, alkynyl, heteroalkynyl, heteroallyl, heteroalkenyl, heteroalkynyl,  
 heterocyclalkyl,  $Z_1$ -Ar or  $Z_1$ -heteroaryl, wherein said alky, allyl,  
 heteroalkenyl, heteroalkynyl, alkoxyl, heteroalkoxy,  $Z_1$ -cyclalkyl,  $Z_1$ -  
 R' is H, alky, alkyl, alkynyl, alkynyl, heteroalkyl, heteroallyl,  
 substituted or unsubstituted;

20  
 cyclalkyl,  $Z_1$ -heterocyclalkyl, or  $Z_1$ -Ar or  $Z_1$ -heteroaryl may be  
 heteroallyl, heteroalkenyl, heteroalkynyl, alkoxyl, heteroalkoxy,  $Z_1$ -  
 heteroallyl, wherein said alky, alkynyl, alkynyl, heteroalkyl,  
 alkoxyl, heteroalkoxy,  $Z_1$ -cyclalkyl,  $Z_1$ -heterocyclalkyl,  $Z_1$ -Ar or  $Z_1$ -  
 alkynyl, alkynyl, heteroalkynyl, heteroallyl, heteroalkenyl, heteroalkynyl,  
 NR',  $(C=O)R'$ ,  $Z_1-C=OR'$ ,  $Z_1-OC(O)R'$ ,  $Z_1-C(=O)OR'$ , alky, allyl,  
 R' is H, an amine protecting group,  $Z_1-OR'$ ,  $Z_1-SR'$ ,  $Z_1-NR'$ ,  $Z_1-$   
 where  
 unsubstituted;

25  
 Ar is aryl or heteroaryl, each of which may be substituted or

19. A method of inhibiting MDM2 expression in a mammal, comprising administering an amount of a compound effective to inhibit said expression, said compound having the Formula (I):



5

I

where

Ar is aryl or heteroaryl, each of which may be substituted or unsubstituted;

10 W is H,  $\text{Z}_n\text{-F}$ ,  $\text{Z}_n\text{-Cl}$ ,  $\text{Z}_n\text{-Br}$ ,  $\text{Z}_n\text{-I}$ ,  $\text{Z}_n\text{-CF}_3$ ,  $\text{Z}_n\text{-NO}_2$ ,  $\text{Z}_n\text{-OR}^1$ ,  $\text{Z}_n\text{-NR}^1\text{R}^2$ ,  $\text{Z}_n\text{-COOR}^1$ ,  $\text{Z}_n\text{-SR}^1$ ,  $\text{Z}_n\text{-(C=O)R}^1$ ,  $\text{Z}_n\text{-O(C=O)R}^1$ ,  $\text{Z}_n\text{-NR}^1\text{(C=O)R}^1$ ,  $\text{Z}_n\text{-NR}^1$ , alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $\text{Z}_n\text{-cycloalkyl}$ ,  $\text{Z}_n\text{-heterocycloalkyl}$ ,  $\text{Z}_n\text{-Ar}$  or  $\text{Z}_n\text{-heteroaryl}$ , wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $\text{Z}_n\text{-cycloalkyl}$ ,  $\text{Z}_n\text{-heterocycloalkyl}$ ,  $\text{Z}_n\text{-Ar}$  or  $\text{Z}_n\text{-heteroaryl}$  may be substituted or unsubstituted;

15 X is  $\text{Z}_n\text{-O}$ ,  $\text{Z}_n\text{-S}$ ,  $\text{Z}_n\text{-NR}^1$ ,  $\text{Z}_n\text{-NR}^1\text{(C=O)}$ ,  $\text{Z}_n\text{-C=O}$ ,  $\text{Z}_n\text{-OC(=O)}$ , or  $\text{Z}_n\text{-C(=O)O}$ ;


20 R<sup>1</sup> and R<sup>2</sup> are independently H, an amine protecting group, an alcohol protecting group, an acid protecting group, a sulfur protecting group, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $\text{Z}_n\text{-cycloalkyl}$ ,  $\text{Z}_n\text{-heterocycloalkyl}$ ,  $\text{Z}_n\text{-Ar}$  or  $\text{Z}_n\text{-heteroaryl}$ , wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $\text{Z}_n\text{-cycloalkyl}$ ,  $\text{Z}_n\text{-heterocycloalkyl}$ ,  $\text{Z}_n\text{-Ar}$  or  $\text{Z}_n\text{-heteroaryl}$  may be substituted or unsubstituted,

$Z'$ -heteroaryl may be substituted or unsubstituted; alkoxyl, heteroalkoxy,  $Z'$ -cycloalkyl,  $Z'$ -heterocycloalkyl,  $Z'$ -Ar or alkenyl, alkynyl, heteroalkyl, heteroaryl, heteroalkenyl, heteroalkynyl, heterocycloalkyl,  $Z'$ -alkyl,  $Z'$ -alkenyl,  $Z'$ -alkynyl,  $Z'$ -heteroalkenyl,  $Z'$ -heteroalkynyl, alkoxyl, heteroalkoxy,  $Z'$ -cycloalkyl,  $Z'$ -heterocycloalkyl,  $Z'$ -Ar or  $Z'$ -heteroaryl, each of which may be substituted or unsubstituted;

where  $W$  is H,  $Z''$ -F,  $Z''$ -Cl,  $Z''$ -Br,  $Z''$ -I,  $Z''$ -CF<sub>3</sub>,  $Z''$ -NO<sub>2</sub>,  $Z''$ -OR',  $Z''$ -NR'<sub>2</sub>,  $Z''$ -COOR',  $Z''$ -SR',  $Z''$ -(C=O)R',  $Z''$ -O(C=O)R',  $Z''$ -NR'(C=O)R',  $Z''$ -C(=O)NR', alkyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, (C=O)NR', alkyl, alkenyl, alkynyl, heteroalkyl, heteroallyl,

$Ar$  is aryl or heteroaryl, each of which may be substituted or unsubstituted;

15 where  
 Ar is aryl or heteroaryl, each of which may be substituted or unsubstituted;



10 expression, said compound having the Formula (III):  
 comprising admixing an amount of a compound effective to inhibit said  
 20. A method of inhibiting MDM2 expression in a mammal,  
 where  $n$  is zero or any integer.

5  $Z$  is an alkylene having at least 1 carbon, or an alkynylene or  
 alkynylene, or alkynylene each having at least 2 carbons, wherein said alkylene  
 10 heterocycle may be fused to an aromatic ring;  
 said heterocycle may be substituted or unsubstituted and wherein said heterocycle ring having 1 or more heteroatoms in said ring, wherein  
 15 or  $R'$  together with  $R^2$  and N forms a saturated or partially unsaturated  
 20 or a heterocyclic may be fused to an aromatic ring;


X is  $Z_n$ ,  $Z_n\text{-O}$ ,  $Z_n\text{-S}$ ,  $Z_n\text{-NR}^1$ ,  $Z_n\text{-NR}^1(\text{C=O})$ ,  $Z_n\text{-C=O}$ ,  $Z_n\text{-OC(=O)}$ , or  $Z_n\text{-C(=O)O}$ ;

R<sup>1</sup> and R<sup>2</sup> are independently H, an amine protecting group, an alcohol protecting group, an acid protecting group, a sulfur protecting group,  
 5 alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n\text{-cycloalkyl}$ ,  $Z_n\text{-heterocycloalkyl}$ ,  $Z_n\text{-Ar}$  or  $Z_n\text{-heteroaryl}$ , wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n\text{-cycloalkyl}$ ,  $Z_n\text{-heterocycloalkyl}$ ,  $Z_n\text{-Ar}$  or  $Z_n\text{-heteroaryl}$   
 10 may be substituted or unsubstituted,  
 or R<sup>1</sup> together with R<sup>2</sup> and N forms a saturated or partially unsaturated heterocycle ring having 1 or more heteroatoms in said ring, wherein said heterocycle may be substituted or unsubstituted and wherein said heterocycle may be fused to an aromatic ring;

15 R<sup>3</sup> is an electron-withdrawing moiety;

Z is an alkylene having at least 1 carbon, or an alkenylene or alkynylene each having at least 2 carbons, wherein said alkylene, alkenylene, or alkynylene may be substituted or unsubstituted; and  
 n = zero or any integer.

20 21. A method of inhibiting MDM2 expression in a mammal, comprising administering an amount of a compound effective to inhibit said expression, said compound having the Formula (III):



III



1/4




FIG. 1




FIG. 2

3/4




FIG. 3

|   |  |  |  |
|---|--|--|--|
| A. CLASSIFICATION OF SUBJECT MATTER   |  | INTERNATIONAL SEARCH REPORT  |  |
| IPC(M) : 51-61K/19, C07C/50Z  |  | Inventor/Designee application No.: PCT/U503/18962  |  |
| According to International Patent Classification (IPC) or both national classification and IPC  |  | Mention classification system followed by classification symbols<br>U.S. : 51/4-64; 56/27  |  |
| Document search performed after than minimum documentation to the extent that such documents are included in the fields searched<br>Please see continuation sheet   |  | Effective date base consulted during the international search (name of data base and, where practicable, search terms used)  |  |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT  |  |  |  |
| Category *<br>X <sup>a</sup> : (KUMAR et al.) Journal of Medical Clinical Chemistry, three page(s), of the relevant passages<br>--: Novel Botanic Compounds Derivatives as Antimicrobial Agents, Volume 46, pages 2813-2815,<br>A: on the Web 30/30/2003.   |  | Relevant to claim No.<br>11-10, 15-18  |  |
| Databases on STN Chemical Abstracts (USA) CA:136:27539 (1)<br>DCAEBRE et al., New testis and testicular hypertension 30(1) pages 111-116, 2002.<br>boronic acids, abs of Analytical Biochemistry 30(1) pages 111-116, 2002.   |  | US 6,083,903 (ADAMS et al.) 04 July 2000 (04.07.2000) see table 2 and examples.<br>1-21  |  |
| US 6,297,217 B1 (ADAMS et al.) 12 October 2001 (12.10.2001) see columns 4-6   |  | US 5,814,622 A (DE NANTUEL et al.) 29 September 1998 (29.09.1998) columns 1-8.<br>1-21   |  |
| Special categories of cited documents:<br>-/- later document引導 and do in earliest the specification but give to<br>prior art which is not considered to<br>be of particular relevance   |  | a. Document relating the central issue of the art which is not considered to<br>be of particular relevance<br>b. earlier publication of present application or after the international filing<br>c. document relating prior art published on or after the international filing<br>d. document relating prior art published on or before the international filing<br>e. document relating prior art published on or before the international filing<br>f. document relating prior art published on or before the international filing<br>g. document relating prior art published on or before the international filing<br>h. document relating prior art published on or before the international filing<br>i. document relating prior art published on or before the international filing<br>j. document relating prior art published on or before the international filing<br>k. document relating prior art published on or before the international filing<br>l. document relating prior art published on or before the international filing<br>m. document relating prior art published on or before the international filing<br>n. document relating prior art published on or before the international filing<br>o. document relating prior art published on or before the international filing<br>p. document relating prior art published on or before the international filing<br>q. document relating prior art published on or before the international filing<br>r. document relating prior art published on or before the international filing<br>s. document relating prior art published on or before the international filing<br>t. document relating prior art published on or before the international filing<br>u. document relating prior art published on or before the international filing<br>v. document relating prior art published on or before the international filing<br>w. document relating prior art published on or before the international filing<br>x. document relating prior art published on or before the international filing<br>y. document relating prior art published on or before the international filing<br>z. document relating prior art published on or before the international filing |  |
| Further documents are listed in the continuation of Box C.<br><input type="checkbox"/> See parent family Annex.   |  |  |  |
| <p>26 February 2004 (06.02.2004)</p> <p>Name and mailing address of the ISA/US<br/>Mail Stop CPT, Amt/ISA/US<br/>Comments Bar, 1231-150<br/>P.O. Box 1450<br/>Commissioner for Patents<br/>Telephone No. 703-308-1235<br/>Fax No. (703) 305-2230</p> <p>Date of mailing of the international search report<br/>19 APR 2004</p> <p>Date of the actual completion of the international search<br/>26 February 2004 (06.02.2004)</p> <p>Additional information<br/>jean F. Volante<br/>Authorized officer</p> <p>jean F. Volante<br/>jean F. Volante</p> <p>Form PCT/ISA/10 (second sheet) (July 1998)</p> |  |  |  |

INTERNATIONAL SEARCH REPORT

PCT/US03/18962

**Continuation of B. FIELDS SEARCHED Item 3:**  
CPLUS, EAST, BIELSTEIN

search terms: structure drawing, HIV, boronic acid, pharmaceutical

